Microsatellite Instability: Definition, Testing & Significance

What Is Microsatellite Instability (MSI)?

Definition

Microsatellite instability (MSI) happens when errors in DNA replication go unchecked, causing mutations in microsatellites—short, repetitive DNA sequences. Under normal circumstances, the DNA mismatch repair (MMR) system detects and corrects these errors. But when this mechanism fails, instability creeps in, leading to an accumulation of mutations that may trigger cancerous changes.

Mechanism

Microsatellites are scattered throughout the genome like genetic signposts. If the MMR system malfunctions—often due to mutations in genes like MLH1, MSH2, MSH6, or PMS2—these signposts become unreliable. The result? Uncontrolled alterations in microsatellite regions, which can pave the way for tumor formation and cancer progression.

Causes of MSI

What triggers MSI? A variety of genetic and epigenetic factors can set this instability into motion:

• Somatic mutations in MMR genes—most frequently MLH1—disrupt repair functions.
• Inherited mutations, like those seen in Lynch syndrome, increase hereditary cancer risk.
• Epigenetic silencing, particularly MLH1 promoter hypermethylation, turns off crucial repair genes.

Key Features of MSI

• Microsatellites consist of short, repeating DNA sequences (1-6 base pairs) found across the genome.
• Healthy cells rely on the MMR system to ensure microsatellite sequences remain stable during cell division.
• In MSI-affected cells, this regulation collapses, leading to unpredictable changes in microsatellite lengths.

Prevalence and Clinical Impact

MSI is not a rare phenomenon—it plays a key role in cancer biology:

15-20% of colorectal cancers exhibit MSI.

30% of endometrial cancers show MSI, highlighting its diagnostic importance.

15% of gastric cancers also harbor MSI, influencing treatment approaches.

More than just a genetic anomaly, MSI acts as a biomarker that helps doctors assess cancer risks, refine diagnoses, and determine personalized treatment strategies, especially in the era of immunotherapy.

Types of Microsatellite Instability

MSI-High (MSI-H)

MSI-High, or MSI-H, refers to a state where microsatellite instability is significantly elevated—usually marked by instability in at least 30% of the genetic markers being analyzed. This level of instability is often associated with severe genetic changes and is commonly found in various cancer types. For instance, in a comprehensive study that explored 39 cancer types, MSI-H prevalence varied, with endometrial carcinoma leading at 31.4%. But what's more interesting? MSI-H tumors often respond more favorably to immune checkpoint inhibitors, making MSI testing a crucial tool for personalizing cancer treatment plans. Research consistently supports the idea that the MSI-H status can predict responses to immunotherapy across multiple cancer types.

MSI-Low (MSI-L)

On the other hand, MSI-Low (or MSI-L) represents an intermediate level of instability. Here, the instability is found in about 15%-29% of the markers being analyzed. While this is not as drastic as MSI-H, it still affects genetic stability and plays a role in cancer development. Interestingly, studies examining different MSI detection methods suggest that MSI-L tumors often present a challenge when it comes to classification, because they fall into a gray area—neither fully fitting the criteria for MSI-H nor MSS (Microsatellite Stable). It's like a middle ground, where things are a bit less clear.

Microsatellite Stable (MSS)

Now, let's look at MSS, or Microsatellite Stable. These are the cancers that show no significant instability—less than 15% of markers exhibit any signs of MSI. In these cases, DNA replication is largely intact, and the microsatellite regions remain stable. But here's where it gets important: MSS tumors are often non-responsive to immune checkpoint inhibitors, which is why MSI testing becomes essential in crafting effective treatment plans. It provides the insights needed to determine whether a patient might benefit from newer immunotherapy treatments, or whether other approaches are needed.

MSI Testing and Analysis: Methods and Technologies

Microsatellite instability (MSI) testing is pivotal in identifying mismatch repair deficiencies in various cancers, notably colorectal cancer. Several laboratory techniques are employed to detect MSI, each with distinct advantages and limitations.

Techniques for MSI Testing

Polymerase Chain Reaction (PCR):

PCR is a widely utilized method for detecting MSI by amplifying specific microsatellite regions and examining them for instability. This technique involves comparing the length of microsatellite sequences in tumor DNA to normal tissue DNA. For example, a study by Peltomäki (2003) showed that PCR is particularly adept at identifying MSI in colorectal cancer, especially in cases linked to Lynch syndrome. And, the pentaplex PCR system, an enhanced version of PCR, takes this even further by offering greater sensitivity and specificity in detecting MSI (Jiang et al., 2018).

Next-Generation Sequencing (NGS):

If you're looking for a more in-depth approach, NGS is where it's at. It offers a comprehensive look at broader genetic mutations, making it possible to detect MSI with high accuracy. In fact, research has shown that NGS has a 97% concordance with traditional PCR and immunohistochemistry techniques (Pabalan et al., 2020). What makes NGS even more exciting is its ability to analyze multiple microsatellite loci at once, providing deeper insights into the genetic instability of cancer cells. Beyond just MSI, NGS also reveals a wider range of mutations—something that's increasingly crucial in the era of precision oncology.

Immunohistochemistry (IHC):

IHC is another key player in the MSI testing field. It focuses on identifying the loss of MMR proteins in tumor tissues, which is a hallmark of MSI. With the help of antibodies, IHC detects proteins like MLH1, MSH2, MSH6, and PMS2, which are often lost in tumors with MSI. In colorectal cancer, IHC and PCR are typically seen as equivalent when it comes to MSI testing (Ruffin et al., 2019). However, while IHC is great at spotting protein loss, it doesn't always catch every type of MSI—particularly when mutations don't affect protein expression but still disrupt microsatellite stability.

High-resolution melting analysis (HRM):

A more recent method, HRM, is gaining traction as a fast, cost-effective way to detect MSI. HRM measures the melting temperature of DNA fragments to assess sequence instability, and studies like Capelle et al. (2014) have demonstrated that HRM can be a reliable alternative to PCR for detecting small-scale microsatellite changes. Although HRM isn't as widely used as PCR, it has distinct advantages in settings where time and cost are critical factors—like clinical trials or initial diagnostic steps.

Liquid biopsies:

Liquid biopsies are the new frontier in MSI testing. These non-invasive tests, which analyze circulating tumor DNA (ctDNA) found in blood samples, offer the promise of earlier detection and monitoring of MSI-high cancers. A study by Wang et al. (2018) highlighted liquid biopsies as a viable method for detecting MSI across a range of cancers, including colorectal. It's a real game-changer for patients who aren't suitable candidates for traditional tissue biopsies, making it possible to track MSI status over time without the need for invasive procedures.

For more information on MSI testing, see Microsatellite Genotyping Service.

MSI Testing Kits

For clinical use, MSI testing kits like the MSI-IVD kit provide a standardized way to detect MSI. These kits typically use PCR methods to assess tumor-agnostic MSI status, which has been validated for solid tumors—especially those exhibiting MSI-H. Shia et al. (2017) pointed out that these kits offer clinicians an essential tool in personalizing treatment, particularly when considering therapies like immune checkpoint inhibitors for MSI-H cancers.

Overview of the different methods used for MSI detection in cancer. (Laura G. Baudrin et al,. 2018)

Comparison of MSI Testing and Analysis Methods

Microsatellite Instability vs. Chromosomal Instability

The types of genomic instability include microsatellite instability (MSI), chromosomal instability, and telomerase inactivation. (Menghui Wang et al,.2022

Emerging Research and Advances in MSI

The Link Between Microsatellite Instability and Cancer

MSI in Colorectal Cancer (CRC)

Colorectal cancer (CRC) is one of the most prominent cancers linked to MSI. Studies show that about 15% of CRCs exhibit MSI, with MSI-High tumors often associated with Lynch syndrome, a hereditary condition that increases the risk of various cancers. MSI testing in CRC is critical for identifying patients who may benefit from targeted therapies, especially immune checkpoint inhibitors.

For more on how MSI testing can aid in CRC diagnosis, visit Microsatellite Instability Analysis.

MSI in Other Cancers

MSI is also found in other cancers, including endometrial cancer, gastric cancer, and ovarian cancer. In endometrial cancer, approximately 25% of tumors show MSI-H, and these tumors often have a better prognosis than those without MSI-H. MSI-H tumors in gastric cancer also show a favorable response to immunotherapy, particularly PD-1 inhibitors.

Clinical Importance

MSI status significantly influences cancer treatment options. For instance, tumors with high MSI (MSI-H) are more likely to respond to immunotherapy drugs like pembrolizumab and nivolumab, which are PD-1 inhibitors. Understanding MSI status is therefore crucial for selecting the right treatment and improving patient outcomes.

Immunotherapy Selection

MSI has emerged as a powerful biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab. MSI-High tumors are more likely to respond to ICIs, offering new hope for patients with advanced cancers that are resistant to conventional therapies.

Prognostic Value

Studies have shown that MSI-High tumors are often associated with better prognosis, particularly in cancers like colorectal and endometrial cancer. MSI status can help clinicians predict the likelihood of treatment success and adjust strategies accordingly.

The Future of MSI in Cancer Diagnosis and Treatment

Microsatellite instability is a powerful tool in the diagnosis and treatment of cancer. As research continues to advance, MSI testing could become a standard part of cancer screenings, leading to more personalized and effective treatments. New genetic therapies and better understanding of MSI could revolutionize cancer care, offering patients a greater chance of survival and a higher quality of life.

Data and Impact of MSI in Cancer Treatment

Here's a quick glance at the prevalence, prognostic impact, and immunotherapy response rates associated with MSI in various cancers:

For more detailed information on MSI testing and related services, visit CD Genomics Microsatellite Instability Analysis.

Conclusion

Microsatellite instability is a game-changer in the fight against cancer. Understanding MSI status provides critical insights into prognosis and treatment response, particularly in personalized medicine. By incorporating MSI testing into clinical practice, we can enhance the effectiveness of cancer therapies, especially immunotherapy. At CD Genomics, we offer advanced services in MSI analysis and testing to help healthcare providers deliver precise and effective cancer treatments.

To learn more about how MSI testing can assist in personalized cancer treatment, visit our Microsatellite Genotyping Service.

References:

1. Jenkins, M. A., Hayashi, S., O'Shea, A. M., Burgart, L. J., Smyrk, T. C., Shimizu, D., ... & Thibodeau, S. N. (2017). Assessment of a streamlined approach to detect Lynch syndrome in colorectal cancer patients. Journal of Clinical Oncology, 35(10), 1082-1089.
2. Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014). Microsatellite instability detection by next-generation sequencing. Clinical Chemistry, 60(9), 1192-1199.
3. Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., Sargent, D. J., ... & Thibodeau, S. N. (2002). Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of Clinical Oncology, 20(4), 1043-1048.
4. Hempelmann, J. A., Lockwood, C. M., Konnick, E. Q., Salipante, S. J., & Pritchard, C. C. (2018). MSIsensor: A novel algorithm for characterizing microsatellite instability in cancer genomes. The Journal of Molecular Diagnostics, 20(1), 105-111.
5. Bartley, A. N., Luthra, R., Saraiya, D. S., & Urbauer, D. L. (2012). Identification of cancer patients with Lynch syndrome: Clinical performance of the revised Bethesda guidelines and comparison of immunohistochemistry to microsatellite instability testing. The Journal of Molecular Diagnostics, 14(4), 305-311. https://doi.org/10.1016/j.jmoldx.2012.02.003
6. Aska, K., et al. (2023). Editorial: Microsatellite and microsatellite instability. Frontiers in Genetics, 14, 1189212.
7. Boland, C. R., & Goel, A. (2010). Microsatellite instability in colorectal cancer. Gastroenterology, 138(6), 2073-2087.e3.
8. Bonneville, R., et al. (2017). Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precision Oncology, 1, 1-15.
9. De Craene, B., et al. (2021). Comparison of microsatellite instability detection by immunohistochemistry, PCR, and NGS in colorectal and endometrial cancer. Scientific Reports, 11, 12880.